It hasn?t been the best start to the week for the S&P/ASX 200 (Index: ^AXJO) (ASX: XJO). In afternoon trade the index is lower by 0.4% to 5,777 points with almost all sectors in the red.
But that hasn?t stopped the four shares listed below from bolting higher. Here?s why they have started the week strongly:
The Kidman Resources Ltd (ASX: KDR) share price is up 9% to 43.5 cents after the lithium miner announced plans to acquire lithium rights through an earn-in agreement with Western Areas Ltd (ASX: WSA). The agreement stretches to 19 of Western Areas’ tenements within…
To keep reading, enter your email address or login below.
It hasn’t been the best start to the week for the S&P/ASX 200 (Index: ^AXJO) (ASX: XJO). In afternoon trade the index is lower by 0.4% to 5,777 points with almost all sectors in the red.
But that hasn’t stopped the four shares listed below from bolting higher. Here’s why they have started the week strongly:
The Kidman Resources Ltd (ASX: KDR) share price is up 9% to 43.5 cents after the lithium miner announced plans to acquire lithium rights through an earn-in agreement with Western Areas Ltd (ASX: WSA). The agreement stretches to 19 of Western Areas’ tenements within the greenstone belt that hosts Kidman’s world-class Earl Grey lithium deposit.
The Liquefied Natural Gas Ltd (ASX: LNG) share price has climbed 5% to 70.5 cents after announcing that Transport Canada has completed its Bear Head TERMPOL review. Although a voluntary review, it is an important step for the company to take to unlock its LNG opportunity in the region.
The Pro Medicus Limited (ASX: PME) share price has jumped almost 10% to $5.34 after the healthcare imaging company announced an on-market buyback of its shares. On April 1 the company will commence buying up to 10% of the ordinary shares on issue during the last 12 months.
The Primary Health Care Limited (ASX: PRY) share price is up 4% to $3.42 despite there being no news out of the healthcare company. But with its shares down by over 16% since the turn of the year, it would appear as though some investors think it has fallen into bargain territory. I’m not convinced and would suggest investors hold off an investment until there has been a notable improvement in its performance.
If you missed out on gains today don't worry. I've tipped these three growth shares to smash the market this year. Are they in your portfolio yet?
For many, blue chip stocks means stability, profitability and regular dividends, often full franked..
But knowing which blue chips to buy, and when, can often be fraught with danger.
The Motley Fool's in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool's Top 3 Blue Chip Stocks for 2017."
Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.
If you're expecting to see the likes of Commonwealth Bank, Telstra and Wesfarmers shares on this list, you'll be sorely disappointed. Not only are their dividends growing at a snail's pace, their profits are under pressure too due to the increasing competitive environment.
The contrast to these "new breed" blue chips couldn't be greater... especially the very real prospect of significant share price gains, something that's looking less likely from the usual blue chip suspects.
The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand - and how quickly the share prices of these companies moves - we may be forced to remove this report.
Click here to claim your free report.
Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.